Faulty gp130 Receptors Reveal How Liver Tumors Switch On

Researchers have revealed how faulty gp130 receptors switch on without a signal and drive benign inflammatory liver tumors. Inflammatory hepatocellular adenomas are benign liver tumors often driven by somatic mutations in gp130 that leave the receptor constitutively active. Using cryo-electron microscopy and mutagenesis, the team mapped how these oncogenic mutants assemble and activate without a ligand. The structures show how altered contacts lock the receptor complex into an active shape that keeps downstream signaling switched on. That constant signal can push liver cells toward abnormal growth and inflammation even when no external cue is present. The work gives a clear molecular explanation for why these adenomas form and why they carry a distinct inflammatory profile. It also points to precise spots that future drugs could target to block the faulty activation. For patients, the findings could improve diagnosis and guide more selective treatments for gp130-driven liver tumors.

image
advertisement
"We will never ask you to login, or register through a third-party advertisement."